Molecular model for neuroendocrine prostate cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Hormonal therapies targeting the androgen receptor (AR) pathway are initial treatments for advanced PCa.
• Resistance to AR pathway inhibitors leads to lethal castration-resistant PCa (CRPC), including aggressive neuroendocrine PCa (NEPC).

Purpose of the Study:

• To review the drivers and facilitators of NEPC progression.
• To define the coordinated processes contributing to NEPC development.
• To identify potential therapeutic opportunities for NEPC.

Main Methods:

• Comprehensive literature review of NEPC drivers.
• Analysis of mechanisms of treatment resistance in PCa.
• Examination of cellular plasticity and transdifferentiation in NEPC development.

Main Results:

• Three coordinated processes contribute to NEPC progression.
• Castration-resistant adenocarcinoma cells acquire lineage plasticity under AR suppression.
• Neuroendocrine (NE)-specific transdifferentiation factors and proliferation factors drive NEPC formation.

Conclusions:

• Treatment-induced NEPC is rising due to potent AR pathway inhibitors.
• Understanding NEPC progression pathways reveals therapeutic vulnerabilities.
• Targeted therapies addressing NEPC drivers offer potential treatment strategies.